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Abstract

Aducanumab has been approved by the US Food and Drug
Administration for treatment of Alzheimer ’s disease (AD).
Clinicians require guidance on the appropriate use of this
new therapy. An Expert Panel was assembled to construct
Appropriate Use Recommendations based on the participant
populations, conduct of the pivotal trials of aducanumab,
updated Prescribing Information, and expert consensus.
Aducanumab is an amyloid-targeting monoclonal antibody
delivered by monthly intravenous infusions. The pivotal trials
included patients with early AD (mild cognitive impairment
due to AD and mild AD dementia) who had confirmed brain
amyloid using amyloid positron tomography. The Expert
Panel recommends that use of aducanumab be restricted to
this population in which efficacy and safety have been studied.
Aducanumab is titrated to a dose of 10 mg/kg over a 6-month
period. The Expert Panel recommends that the aducanumab
be titrated to the highest dose to maximize the opportunity for
efficacy. Aducanumab can substantially increase the incidence
of amyloid-related imaging abnormalities (ARIA) with brain
effusion or hemorrhage. Dose interruption or treatment
discontinuation is recommended for symptomatic ARIA and
for moderate-severe ARIA. The Expert Panel recommends
MRIs prior to initiating therapy, during the titration of the drug,
and at any time the patient has symptoms suggestive of ARIA.
Recommendations are made for measures less cumbersome
than those used in trials for the assessment of effectiveness
in the practice setting. The Expert Panel emphasized the
critical importance of engaging in a process of patient-centered
informed decision-making that includes comprehensive
discussions and clear communication with the patient and care
partner regarding the requirements for therapy, the expected
outcome of therapy, potential risks and side effects, and the
required safety monitoring, as well as uncertainties regarding
individual responses and benefits.
Key words: Alzheimer ’s disease, aducanumab, Aduhelm™,
appropriate use, titration, ARIA, amyloid imaging, MRI.

A

ducanumab (Aduhelm™) has been approved
by the US Food and Drug Administration
(FDA) for the treatment of Alzheimer’s disease
(AD). The Prescribing Information for aducanumab (1)
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provides key facts on aducanumab such as dose, titration,
pharmacokinetics, and side effects. The Clinical Studies
section describes the clinical trials that led to the approval
of aducanumab. Many details of the clinical use of this
new agent are not detailed in the Prescribing Information
(1) and there is a need for specific recommendations
regarding how to use aducanumab appropriately.
Experts with experience in AD research, AD clinical
trials and drug development, AD clinical care, and use
of aducanumab were assembled to develop consensus
recommendations for the appropriate use of aducanumab
in clinical practice.
The Prescribing Information (1) provides the “on label”
prescribing instructions. The Expert Panel recommends
that the appropriate use of aducanumab in real-world
clinical practice should pragmatically mimic the use of
aducanumab in the EMERGE and ENGAGE clinical trials
that led the FDA to approve aducanumab. After the initial
Prescribing Information was published, the FDA adjusted
the indication section from “indicated for the treatment
of Alzheimer’s disease” to “indicated for the treatment
of Alzheimer’s disease…should be initiated in patients
with mild cognitive impairment or mild dementia stage
of the disease, the population in which treatment was
initiated in clinical trials” (1, 2). Some of the Expert Panel
recommendations are more specific or more restrictive
than the information provided in the Prescribing
Information (1). The recommendations are within the
scope of use articulated in the Prescribing Information
(1). The Expert Panel describes the appropriate use
of aducanumab for the practicing clinician; we do
not address trial outcomes, approval strategies, cost,
insurance coverage, or reimbursement issues. The
Expert Panel recommendations apply to practices in the
Unites States where aducanumab is currently approved.
Recommendations may change as more data on the use
of aducanumab and more data from the trials become
available. These recommendations are meant to assist
practitioners in using aducanumab safely; they do not
replace clinician judgement in the delivery of care to
individual patients.
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Overview

Appropriate Patient

Aducanumab is a monoclonal antibody directed to
the N-terminus of the amyloid beta peptide (Aß). It was
derived through a process of reverse translation in which
blood lymphocytes from healthy elderly individuals who
were cognitively normal or had unusually slow cognitive
decline served as a source of antibody genes for the
generation of recombinant human antibodies (3).
The Expert Panel recommends that patients treated
with aducanumab closely resemble those included in
the pivotal clinical trials (4, 5). Pragmatic adjustments
will be required for use of aducanumab outside of the
trial setting, and the translation of clinical trial protocol
requirements to clinical practice is summarized in
Table 1. Efficacy and safety have been assessed in the
early AD population of patients with mild cognitive
impairment (MCI) due to AD and mild dementia due to
AD confirmed by amyloid positron emission tomography
(PET) and are unknown for individuals with preclinical
AD, those with more severe AD dementia, or those with
cognitive impairment that is not confirmed to be AD by
Aß studies.

Diagnosis
The Expert Panel recommends that patients
appropriate for treatment with aducanumab have
a diagnosis of early AD established by a diagnostic
evaluation that includes: 1) detailed history that
is sufficient to establish the nature and time course of
cognitive symptoms, functional changes, and behavioral
status; 2) objective corroboration of cognitive decline
using standardized testing; 3) detailed neurological
and physical examination; 4) review of all current
medications and supplements; 5) laboratory testing
sufficient to exclude other concomitant disorders that
can cause cognitive decline including a complete blood
count, electrolyte panel, thyroid stimulating hormone,
lipids and triglycerides, liver function tests, and serum
vitamin B12 level; and 6) magnetic resonance imaging
(MRI) of the brain to rule out other conditions that could
present with cognitive decline (e.g., normal pressure
hydrocephalus, vascular dementia, slow going neoplasm,
subdural hematoma) and to assess possible exclusions

Table 1. Clinical trial enrollment criteria and appropriate use criteria for aducanumab in clinical practice

Participant Feature

Clinical Trial Enrollment Criteria

Appropriate Use in Clinical Practice

Diagnosis

Clinical criteria for MCI due to AD or mild AD dementia

Clinical criteria for MCI due to AD or mild AD dementia

Amyloid status

Amyloid positive PET (visual read)

Amyloid positive PET (visual read) or CSF findings consistent with AD

Neurological examination

Non-AD neurological disorders, stroke, and TIA excluded

Non-AD neurological disorders excluded

Medical history

Excluded: clinically significant systemic illness; diabetes Stable medical conditions required; clinical decision can be exercised on the
than cannot be managed; uncontrolled hypertension (systolic ability of the patient to participate safely with the therapeutic regimen
> 165; diastolic > 100); history of cancer unless in remission
for 5 years or localized to skin or prostate; impaired liver
function; hepatitis; HIV infection

Age

Scale scores at baseline

Genetic testing

Cardiovascular history

Psychiatric history
Reproductive status
Clotting status

Concomitant medications
Baseline MRI

Care support

Informed consent

50-85

Younger or older patients meeting all other criteria for treatment could be
considered candidates for aducanumab

CDR Global Score 0.5; MMSE 24-30; RBANS Delayed MMSE 21-30 or equivalent such as MoCA 17-30
Memory Score of 85 or less
Consent for APOE genotyping

Genotyping should be discussed with the patient/care partner. ARIA risk
should be described, and the patient’s preferences assessed.

Angina; myocardial infarction; congestive heart failure Stable cardiovascular conditions required; clinical decision can be exercised
excluded
on the ability of the patient to participate safely with the therapeutic regimen

Unstable psychiatric illness in the past 6 months; alcohol Must be stable psychiatrically; clinical decision can be exercised on the ability
or substance abuse in the past year; use of cannabinoids; of the patient to participate safely with the therapeutic regimen
positive urine tests for excluded substances
Female subjects who are pregnant or breast feeding Female subjects who are pregnant or breast feeding excluded; female subjects
excluded; female subjects who are of childbearing age must who are of childbearing age must be practicing contraception
be practicing contraception
Bleeding disorders, anticoagulants excluded

Patients on anticoagulants are excluded

Baseline MRI finding that excluded participation: acute or
subacute hemorrhage, macrohemorrhage, greater than 4
microhemorrhages, cortical infarction (>1.5 cm), 1 lacunar
infarction (>1.5 cm), superficial siderosis, or diffuse white
matter disease

Patients should be excluded if there is evidence of acute or subacute
hemorrhage, macrohemorrhage, greater than 4 microhemorrhages, cortical
infarction (>1.5 cm), 1 lacunar infarction (>1.5 cm), > 1 area of superficial
siderosis, or diffuse white matter disease

Cholinesterase inhibitors and memantine allowed

Reliable informant or care partner

Must be signed by participant and care partner

Patients can be on standard of care with cholinesterase inhibitors and
memantine

May be living independently or with a care partner

Patient and care partner must understand the nature and requirements
of therapy (e.g, monthly infusions to be performed indefinitely) and the
expected outcome of therapy (slowing of decline of clinical features)

Aß – amyloid beta protein; AD – Alzheimer’s disease; APOE – apolipoprotein E; CDR – Clinical Dementia Rating; cm – centimeter; CSF – cerebrospinal fluid; HIV – human
immunodeficiency virus; MMSE – Mini Mental State Examination; MoCA – Montreal Cognitive Assessment; MRI – magnetic resonance imaging; PET – positron emission
tomography; RBANS – Repeatable Battery for the Assessment of Neuropsychological Status; TIA – transient ischemic attack
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for use of aducanumab (discussed below) (6-8). This
assessment will determine if the patient has clinical
findings consistent with early AD.
Patients with early AD meet the clinical criteria of
stage 3 and 4 of the FDA staging approach (9). Stage 3
consists of individuals with subtle or more apparent
detectable abnormalities on sensitive neuropsychological
measures and mild but detectable functional impairment.
The functional impairment in this stage is not severe
enough to warrant a diagnosis of overt dementia. Stage 4
includes individuals with cognitive impairment and mild
but definite functional decline.
To quantify the cognitive and functional changes, early
AD patients in the aducanumab trials had scores on the
Clinical Dementia Rating (CDR) (10) global rating of 0.5.
This instrument assesses cognitive (memory, orientation,
judgment, and problem solving) and functional
(community affairs, home and hobbies, and personal
care) domains. In addition, trial participants had Mini
Mental State Examination (MMSE) (11) scores of 24-30.
The MMSE is commonly used in clinical practice and is
a useful tool for identifying appropriate patients. The
standard error of measurement on the MMSE is 1 point,
and the minimum detectable difference is 3 points (12,
13). The test-retest reliability of MMSE is 2-4 points (14).
These studies indicate that scores of 21 and higher would
not be detectably different from the range of MMSE
scores of patients included in the pivotal trials (MMSE
range of 24-30). The Phase 1B study of aducanumab
had encouraging results in patients with MMSE scores
of 20-30 (15). The Expert Panel recommends that
patients with MMSE scores of 21 or higher or who have
a similar level of performance on an alternate reliable
and valid assessment are appropriate for treatment with
aducanumab. An alternative assessment that provides
reliable information similar to that of the MMSE is the
Montreal Cognitive Assessment (MoCA) (16). The MoCA
is a more challenging test than the MMSE resulting in
lower scores when compared to the MMSE. Scores of
17 and higher on the MoCA are equivalent to MMSE
scores of 21-30 in early symptomatic AD (17). In settings
where neuropsychological testing is available, a diagnosis
of early AD can be based on more extensive cognitive,
functional, and behavioral assessments (18).

Use of cognitive enhancing agents in aducanumab
candidates
A newly diagnosed patient with MCI due to AD
may be started on aducanumab since cholinesterase
inhibitors and memantine are not approved for
this stage of AD. Patients with early AD may be on a
cholinesterase inhibitor or memantine when referred
for possible treatment with aducanumab; these patients
can remain on their standard of care while being treated
with aducanumab. Patients diagnosed with mild AD
dementia can have treatment with aducanumab before

or following initiation of treatment with a cholinesterase
inhibitor. If patients with MCI progress to mild AD
dementia, treatment with a cholinesterase inhibitor
(donepezil, rivastigmine, galantamine) can be considered.
Memantine is not approved for mild AD dementia. If
patients progress to moderate or severe AD, memantine
treatment can be considered as monotherapy or in
conjunction with a cholinesterase inhibitor (19).

Amyloid status
All patients included in the pivotal trials had
positive amyloid positron emission tomography
(PET). Demonstration of amyloid burden is critical
to establishing the presence of the target for amyloid
lowering therapies. The clinical diagnosis of AD is
often not confirmed by amyloid studies and up to 40%
of patients diagnosed with early AD do not have the
amyloid pathology when studied with amyloid imaging
(20). Appropriate Use Criteria of amyloid imaging
suggest that the imaging is appropriate when: a) there
is a cognitive complaint and cognitive impairment has
been objectively confirmed impairment; b) AD is a
possible diagnosis, but the diagnosis is uncertain after a
comprehensive evaluation by a dementia expert; and c)
knowledge of the presence or absence of amyloid-beta
pathology is expected to increase diagnostic certainty
and alter management (21). These criteria are fulfilled
in the situation where a patient is being considered for
treatment with aducanumab: they have the symptoms of
early AD, additional diagnostic certainty is needed, and
management will be based on the outcome.
Three amyloid PET tracers are approved by the FDA:
florbetapir, florbetaben, and flutametamol (22-24).
Table 2 provides the criteria for a positive scan for each
tracer. Scan interpretation is best done by radiologists
or nuclear medicine specialists; training programs
for amyloid PET interpretation are available for each
ligand. The Expert Panel recommends that programs
offering aducanumab treatment and using amyloid
PET to confirm the diagnosis of AD should ensure the
availability of individuals properly trained in amyloid
PET interpretation.
Lumbar puncture and assessment of cerebrospinal
fluid (CSF) biomarkers (Aβ42, Aβ40 total tau,
phosphorylated tau [p-tau]) provide an alternative to
amyloid PET and are more widely available (25). Several
CSF measures can be indicative of the presence of AD
including low Aβ42, low Aβ42/Aβ40 ratio, abnormal
Aβ42/tau ratios, and abnormal Aβ42/p-tau ratios
(26-28). Practitioners should use Clinical Laboratory
Improvement Amendments (CLIA)-certified facilities and
follow the laboratory’s guidelines for optimal AD-related
assays. If CSF results are ambiguous, amyloid imaging
is recommended. Amyloid PET and CSF AD signature
studies provide equally valid information (29); CSF Aβ42
levels correlate inversely with brain amyloid on PET with
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Table 2. Criteria for a positive amyloid PET for the three approved amyloid PET tracers (from drugs@FDA: FDAApproved Drugs)

PET Tracer

Criteria for Interpreting as a Positive Scan

Florbetaben (NeuraceqTM)

β-amyloid positive - smaller area(s) of tracer uptake equal to or higher than that present in white matter extending beyond the white matter
rim to the outer cortical margin involving the majority of the slices within at least one of the four brain regions (“moderate” β-amyloid
deposition), or a large confluent area of tracer uptake equal to or higher than that present in white matter extending beyond the white matter
rim to the outer cortical margin and involving the entire region including the majority of slices within at least one of the four brain regions.

Florbetapir (AmyvidTM)

Flutemetamol (VizamylTM)

A positive scan will have either: Two or more brain areas (each larger than a single cortical gyrus) in which there is reduced or absent graywhite contrast; OR, one or more areas in which gray matter radioactivity is intense and clearly exceeds radioactivity in adjacent white matter.

Positive scans show at least one cortical region with reduction or loss of the normally distinct grey-white matter contrast. These scans have
one or more regions with increased cortical grey matter signal (above 50-60% peak intensity) and/or reduced (or absent) grey- white matter
contrast (white matter sulcal pattern is less distinct). A positive scan may have one or more regions in which grey matter radioactivity is as
intense or exceeds the intensity in adjacent white matter.

CSF levels declining as Aβ is deposited in the cortex (30).
Changes in CSF Aβ42 levels precede changes in amyloid
PET (31); individuals with abnormal CSF and normal
amyloid PET imaging are usually without symptoms
and they lack evidence of amyloid plaques which are the
target of aducanumab. The Expert Panel recommends
that these patients not be treated with aducanumab.
Re-imaging with amyloid PET in 1-3 years may be
warranted in this group of individuals.
Lumbar puncture can be performed by physicians,
nurse practitioners, or physicians’ assistants/associates
with low patient morbidity and high safety (32). Lumbar
puncture may not be possible in those with pathological
or surgical changes of the lumbar spine; fluoroscopic
guidance may be useful in such cases. Lumbar puncture
is contraindicated in those with clotting disorders or
who are on anticoagulants. Prothrombin time (PT) and
partial thromboplastin time (PTT) can be obtained to
ensure normal clotting parameters before proceeding
with lumbar puncture.
Amyloid imaging or CSF biomarker analyses in
persons with the clinical features of early AD will reveal
that some of these cognitively impaired individuals do
not have AD, exhibit evidence of neurodegeneration, and
fulfill criteria for suspected non-Alzheimer pathology
(SNAP) (33). Discovery of the non-amyloid status of these
individuals assists clinicians in making management
decisions (34). The Expert Panel recommends that
individuals with SNAP not be treated with aducanumab.
Lumbar puncture with findings consistent with
AD or PET with elevated brain amyloid confirm the
diagnosis of AD in patients with the clinical syndrome
of early AD. Failure to confirm the diagnosis of AD
with amyloid biomarkers could result in administering
aducanumab to patients who do not have AD and who
lack the target pathology of the agent. The Expert Panel
recommends that all patients considered for treatment
with aducanumab have the diagnosis of AD confirmed by
clinically validated amyloid studies such as amyloid PET
or CSF analysis.

Genetic testing
Genetic testing to determine the apolipoprotein E
(APOE) genotype of the participants was required in
the pivotal trials. ARIA of the effusion (ARIA-E) or

hemorrhagic (ARIA-H) type are more common in
APOE ε 4 (APOE-4) gene carriers and understanding
this effect in trials is important (35). ARIA may be more
common in APOE-4 homozygotes and can be severe
(36). The Prescribing Information (1) instructions for
use of aducanumab do not require APOE genotyping
and the dosing and monitoring of individuals with and
without an APOE-4 allele are identical. The Expert Panel
recommends that patients and care partners be engaged
in a patient-centered discussion of the risk that an APOE4 genotype confers for the risk of ARIA. This discussion
will determine if genotype information would influence
their decision to be treated with aducanumab and if they
wish to pursue APOE genotyping.
If patients, care partners, or referring clinicians
request APOE genotyping prior to the decision to use
aducanumab or if the individual has determined their
genotype through a commercial service, the Expert Panel
recommends that the clinician be prepared to discuss
the increased risk for ARIA in the presence of an APOE4 allele as well as the consequences, monitoring, and
management of ARIA if it occurs (discussed below).
Genotyping provides transgenerational information on
risk of AD for first degree relatives. Parents, siblings, and
children of APOE-4 heterozygotes have a 50% chance
of being an APOE-4 carrier with an increased risk of
AD, and first-degree relatives of APOE-4 homozygotes
have a 100% chance of being APOE-4 carriers and
have an increased risk of AD. Clinicians may request
genetic counseling to assist patients and caregivers in
understanding the implications of their genotype (37, 38).

Neurological, medical, and psychiatric illness
The Expert Panel recommends that patients
with neurological disorders that could account for or
contribute to the clinical syndrome of the patients not be
treated with aducanumab. This would include patients
with parkinsonism, evidence of stroke or widespread
white matter ischemic changes, or rapidly progressive
dementia. Similarly, recent major psychiatric illness
may compromise the ability to adhere to therapy and
treatment should be deferred until behavioral stability
is established. Poorly controlled or serious medical
illnesses (e.g., cancer, heart failure) were exclusions
for trial participation and if such illnesses are present
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in an individual being considered for treatment with
aducanumab, the medical condition should be managed
and stable prior to initiating treatment. Exclusionary
factors are often less rigorous in routine care than in
clinical trials but should not be so different as to threaten
the generalizability of the trial results to the patient or
increase the risk of treatment (39).
Aducanumab has not been studied for its reproductive
or teratogenic effects and aducanumab should be
administered to younger sexually active AD patients only
if they are using contraceptive methods.

Clotting status
Aducanumab is associated with ARIA. Patients
with evidence of microhemorrhage on MRI (discussed
below) or with clotting abnormalities or who were on
anticoagulants were excluded from the pivotal trials.
It is not known if these exclusions affected the rate of
microhemorrhage associated with aducanumab
therapy. The risk of severe ARIA in a person receiving
anticoagulants or with a clotting disorder is sufficient to
exclude them from treatment with aducanumab. Platelet
anti-aggregation agents are allowable as concomitant
therapy. Lumbar puncture for confirmation of amyloid
status should not be performed on patients being
treated with anticoagulants; the occurrence of perispinal
hemorrhage and spinal cord compression are low but can
occur and the risk should be avoided (40).

Concomitant Medications
There are no adverse drug-drug interactions noted
in the Prescribing Information (1). Drugs used in
routine care of patients with AD were allowed to be
used by participants in the pivotal trials. The Expert
Panel agreed that aducanumab may be co-administered
with other drugs used in the treatment of AD including
cholinesterase inhibitors (donepezil, rivastigmine,
galantamine), memantine, and psychotropic agents
(antidepressants, antipsychotics, hypnotics).

MRI prior to initiating treatment
Concern for the occurrence of ARIA motivated
avoiding administration of aducanumab to patients who
had evidence of substantial cerebrovascular disease at
baseline in the pivotal trials. The protocol excluded
patients who had acute or subacute hemorrhage,
macrohemorrhage, greater than 4 microhemorrhages,
cortical infarction (>1.5 cm), 1 lacunar infarction (>1.5
cm), diffuse white matter disease, or any areas of
superficial siderosis (41). The Expert Panel recommends
that these exclusions be observed in clinical practice
when choosing appropriate patients for treatment
with aducanumab. An MRI including T1, T2 or fluid
attenuated inversion recovery (FLAIR), T2* gradient

recalled echo (GRE) sequences or susceptibility weighted
imaging (SWI), and diffusion weighted imaging should
be obtained within 1 year of initiating treatment with
aducanumab (and more recently if there is any evidence
of stroke since the last MRI). A 3-Tesla magnet MRI will
reveal more microhemorrhages than a 1.5 Tesla magnet
device, and SWI sequences will reveal more ARIA than
GRE images (42). Changes from a baseline scan is the
basis for ARIA-related decision making, and the Expert
Panel recommends that practitioners use the same MRI
device with the same imaging protocol for a given patient
whenever possible to assist in comparing the images.
Computerized tomography (CT) does not provide
sufficient information to determine risk at baseline or to
monitor ARIA; individuals who cannot have an MRI (e.g.,
have a pacemaker incompatible with MRI, metallic brain
vessel aneurysm clip, or metallic object in an eye) should
not be treated with aducanumab.

Knowledgeable engagement
In the clinical trials of aducanumab, informed consent
from the patient and care partner were required for
participation. In clinical care, formal informed consent
is not required but a similar approach should be used to
ensure that the patient and care partner/family member/
companion understand the requirements for treatment
and the expected outcome of therapy. Patients with
early AD have the cognitive capacity to comprehend
the possible benefit or harms of aducanumab treatment.
Key aspects of informed therapy include discussion of
requirements for monthly infusions and periodic MRI
and the risk of adverse events including ARIA. The
anticipated duration of therapy is indefinite and longer
treatment with disease-modifying agents is expected to
have greater effects on the disease course (43); the optimal
duration of therapy is unknown and it may be possible
to reduce the frequency of infusions when amyloid levels
have been substantially reduced but this has not yet been
determined. Those considering aducanumab therapy
should understand that the expected benefit is slowing
of cognitive and functional decline; improvement of the
current clinical state is not anticipated. Patients should
have disease state education regarding the course of
AD and the availability of cognitive enhancing agents.
Educational programs can improve mood, reduce anxiety,
and ameliorate caregiver burden (44). The Expert Panel
recommends that appropriate use of aducanumab
includes providing information on the requirements for
treatment and the expected outcomes, potential risks and
side effects, and burdens related to administration and
monitoring.
Special efforts are required to engage minority
patients and to communicate the need for care and
the opportunities for treatment. Minority patients
report being “unheard” in medical conversations (45).
Historically, use of AD therapies such as cholinesterase
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Figure 1.

Aducanumab dosing and MRI monitoring schedule (Prescribing Information (1) and Expert Panel
recommendation; © J Cummings; illustrator M de la Flor, PhD)

inhibitors has been less in African American, Latino,
and Asian populations than among White AD patients
(46). Addressing concerns about the deleterious effects
and stigma of diagnosis and raising awareness of
potential benefits of disease identification and treatment
may influence the willingness of minority patients to
discuss cognitive symptoms with clinicians (47). Minority
patients often prefer clinicians who share their language
and culture (48). The Expert Panel recommends that
clinicians strive to engage diverse patients in diagnosis
and treatment discussions with the goal of achieving
equity among diverse groups in the use of aducanumab.

Appropriate Treatment
Aducanumab initiation and Titration
Aducanumab infusions are done monthly and require
approximately one hour to complete. Infusions should
be at least 21 days apart. The first and 2nd infusion dose
is 1 mg/kg; the 3rd and 4th infusions are with doses of 3
mg/kg; the 5th and 6th infusions are dosed at 6 mg/kg;
the 7th infusion and beyond involve monthly infusions
of 10 mg/kg (Figure 1). Aducanumab is supplied in
vials of 170 mg/1.7 mL or 300 mg/3 mL and is added
to an infusion bag of 100 mL of 0.9% sodium chloride.
The data from the pivotal trials and the Phase 1B trial
of aducanumab suggest that 10 mg/kg is the target
dose (15). Lower doses may not produce benefit and
may cause ARIA. The Expert Panel recommends that
patients be titrated to 10 mg/kg. If that is not possible, the
clinician should engage in a patient-centered discussion
as to whether to continue treatment with lower doses of
aducanumab.
Management of missed doses has not been studied.
The Expert Panel recommends that if a patient misses a
dose, the next infusion should be administered as soon
as possible at the dose administered in the previous
infusion. If a patient misses three or more doses and
requires continued treatment, titration should be

re-initiated beginning at a dose level one step below that
previously administered (e.g., if the patient was at 6 mg/
kg previously, they would resume at a dose level of 3
mg/kg) with the dose increased every other month as
described for treatment initiation.
Infusions may be done in a clinician’s office; in general
infusion centers providing intravenous (IV) therapies
to patients with cancer, arthritis, or other disorders; in
specialized aducanumab infusion facilities; or at home.
Home infusions are administered by a visiting nurse.
General infusion center personnel may not be familiar
with interacting with cognitively impaired patients and
may require specialized training to ensure that the patient
has a positive experience fostering a sense of well-being
and conducive to treatment adherence. Clinicians should
ask patients about any recent symptoms suggestive of
ARIA before each infusion. Evidence of coagulopathy,
symptoms suggestive of stroke, or poorly controlled
blood pressure may be reasons to defer therapy and
reevaluate the patient.

ARIA monitoring and management
The most common adverse event produced by
aducanumab is ARIA. Aducanumab is associated with
a substantially increased rate of ARIA compared to
rates observed in natural history studies or trial placebo
groups. ARIA (ARIA-E and ARIA-H) occurred in 35.2%
of patients on high dose aducanumab compared to an
occurrence rate of 2.7% in the placebo group (Table 3)
(5). Among those receiving aducanumab, ARIA-E was
most commonly observed in participants who were
APOE-4 gene carriers (43%) and least often in those
without the APOE-4 gene (20.3%). Both symptomatic
and asymptomatic ARIA are more common in APOE-4
gene carriers. Thirty percent of ARIA-E were mild (<
5cm on FLAIR imaging with hyperintensity confined to
one location); 58% were moderate (5-10 cm involving
more than one location); and 13% were severe (> 10 cm)
(2). Most ARIA occurs in the first 8 months of treatment
during the titration period but can occur any time in the
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treatment course. ARIA was successfully managed in
most patients participating in the pivotal trials without
discontinuing treatment; ARIA led to discontinuation
from the trials in 6.2% of patients on aducanumab and
0.6% of patients on placebo.
Most ARIA events (74%) detected by MRI have
no accompanying symptoms. Among those with
symptomatic ARIA, symptoms were mild in 67.7%,
moderate in 28.3%, and severe in 4% (4). The most
common symptoms reported were confusion or altered
mental status (5%), dizziness (4%), visual disturbances
(2%), and nausea (2%) (2). ARIA episodes typically
resolved in 4-16 weeks.
Table 3. Occurrence of ARIA in the entire population
and in participants with and without the APOE-4 allele
in the two pivotal trials combined (10 mg/kg dose) (5)

Participant Group

ARIA-E and ARIA-H (overall population)

ARIA-E (overall population)

Placebo

Aducanumab

2.7%

35.2%

8.7%

28.3%

3.9%

20.3%

10%

ARIA-E with symptoms

10.3%

ARIA-E APOE-4 carriers

2.2%

ARIA-H (overall population)
ARIA-E APOE-4 noncarriers

Trial discontinuations due to ARIA

0.6%

monthly MRIs obtained until treatment can be re-initiated
or a decision is made to terminate treatment. If three or
more doses are missed before restarting aducanumab,
the dose should be re-titrated as described above.
Aducanumab should not be re-initiated in patients with
severe symptomatic ARIA (e.g., seizure, stroke-like
syndromes).
If patients are asymptomatic and the MRI reveals
severe or moderate ARIA-E or severe or moderate
ARIA-H (Table 4), treatment is suspended, and
management follows the procedures described for
patients with symptoms (Figure 2). If asymptomatic
patients have mild ARIA-E or mild ARIA-H, treatment
is continued, and MRIs are obtained at monthly intervals
until ARIA-E is resolved or ARIA-H is stable. There is
limited information on best practices for management
of moderate ARIA-E or moderate ARIA-H and
recommendations may evolve.

41%

Figure 2. Management strategy for ARIA. Patients with
severe symptomatic ARIA are not re-titrated and are
not candidates for further treatment with aducanumab
(Expert Panel recommendation; © J Cummings; illustrator
M de la Flor, PhD)

26%
43%

6.2%

MRIs should be obtained at least 1 year prior to the
initiation of treatment and more recently (preferably
within 6 months) if there is any suggestion of an
intervening central nervous system event (e.g., sudden
worsening, transient ischemic attacks). After treatment
initiation, MRIs should be obtained before the 5th
infusion (before initiating the 6 mg/kg dose); prior to
the 7th infusion (before infusion of the first dose of 10
mg/kg); and before the 12th infusion (e.g., before the 6th
dose of 10 mg/kg). Given the rate of ARIA-E with the
10 mg/kg dose in the phase 3 studies, especially among
APOE-4 carriers, some clinicians may decide to obtain
an MRI before the 10th dose, after 3 doses of 10 mg/kg
have been administered to avoid failure to detect ARIA
that may require active management. MRI studies for
ARIA should include FLAIR, T2* GRE and quick DWI.
An optional 4th sequence would be either 3D T1 or 3D
T2 SPACE (depending on the type of MRI available).
In addition to these scheduled MRIs, patients should
have an MRI whenever they have symptoms suggestive
of ARIA such as headache, vomiting and/or nausea,
confusion, dizziness, visual disturbance, gait difficulties,
loss of coordination, tremor, transient ischemic attack,
new onset seizures, or significant and unexpected acute
cognitive decline.
If patients with ARIA (ARIA-E or ARIA-H) have
symptoms, treatment should be suspended, and a clinical
assessment and neurological examination performed
(Figure 2). MRI should be repeated in 1 month; if
the ARIA-E has resolved or the ARIA-H is stabilized,
treatment can be resumed. If ARIA-E has not resolved
and ARIA-H is worsening, treatment is withheld, and

Clinicians providing aducanumab need access to MRI
facilities and to radiologists familiar with detection and
reporting of ARIA-E and ARIA-H. Inexperienced readers
may fail to detect signs of ARIA when interpreting scans
(35, 49). CT is not sufficient for ARIA monitoring.

Non-ARIA side effect monitoring
Overall adverse events were experienced by 86.9% of
patients on placebo and 91.6% of patients on high dose
aducanumab in the pivotal trials (5). Adverse events
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Table 4. MRI severity levels of ARIA-E and ARIA-H as described in the aducanumab Prescribing Information (1)

ARIA-Type

ARIA-E

FLAIR hyperintensity confined to sulcus FLAIR hyperintensity 5 to 10 cm, or
and or cortex/subcortical white matter
more than 1 site of involvement, each
in one location < 5 cm
measuring < 10 cm

Mild

Moderate

Severe

ARIA-H microhemorrhage

≤ 4 new microhemorrhages

5 to 9 new microhemorrhages

10 or more new microhemorrhages

ARIA-H superficial siderosis

1 focal area of superficial siderosis

2 focal areas of superficial siderosis

reported more often in patients receiving aducanumab
included headache (20.5% vs 15.2% in placebo), falls
(15% vs 11.8% in placebo), and diarrhea (8.9% vs 6.8%
in placebo). Serious adverse events occurred in 13.9%
of patients on placebo and 13.6% of patients receiving
aducanumab. There were 5 fatalities among patients
on placebo and 8 among those on aducanumab. The
Expert Panel recommends vigilance for all potential side
effects in patients treated with aducanumab with special
attention to headache, falls, and diarrhea.

Effectiveness monitoring
Efficacy was assessed in the pivotal trials using the
Clinical Dementia Rating – Sum of Boxes (CDR-sb)
(10), Alzheimer’s Disease Assessment Scale – Cognitive
Subscale (ADAS-cog) (50), Alzheimer ’s Disease
Cooperative Study Activities of Daily Living MCI
version (ADCS-ADL-MCI) scale (51), MMSE (11), and
the Neuropsychiatric Inventory (NPI) (52). These tools
were used to assess patients directly (ADAS-Cog; MMSE;
portions of the CDR-sb) or through interviews with care
partners (ADCS-ADL-MCI; NPI; parts of the CDR-sb).
The time of administration of this panel is approximately
2 hours and some of the instruments take substantial
training and experience to be administered reliably (e.g.,
CDR-sb) (53). Use of such a battery is impractical in
many medical or neurological practice settings. Objective
assessments requiring less time and training may
provide insight in the patient’s course; and the clinician
should employ tools commonly used in practice. No
improvement in cognition or function is anticipated with
disease modifying therapy (DMT); slowing of decline and
prolongation of the optimal clinical state is the goal of
treatment (43). The heterogeneity of decline in early AD
makes it difficult to conclude that a slowly progressive
disorder is being slowed more by aducanumab (54).
Several means of monitoring treatment effects in the
open label practice environment can be considered. The
mean change on the MMSE over twelve months in the
placebo group in PRIME was (-2.5), in ENGAGE (-3.5),
and in EMERGE (-3.3). This provides a range of scores
against which the decline in the patient on aducanumab
might be compared. The drug-placebo differences
observed in EMERGE may guide clinician expectations
for the impact of aducanumab on disease progression:
this included 18%-27% differences on cognitive decline,
40% difference on functional decline, and 87% difference
in behavioral changes. The decline in the late period of

FLAIR hyperintensity measuring > 10
cm, often with significant subcortical
white matter / sulcal involvement. May
involve one or more separate sites
> 2 focal areas of superficial siderosis

MCI due to AD is predictable based on observations
in the early MCI period (55). The clinician and care
partner may observe differences in the rate of change
when aducanumab is introduced and titrated to the 10
mg/kg dose.
The MMSE (11) is commonly used in clinical settings
and may be used to monitor patients treated with
aducanumab. The MoCA is an alternative to the MMSE
(16). The AD8 is a brief informant interview assessing
orientation, judgement, memory, and function (56, 57).
The AD8 has been shown to have concurrent validity
with the CDR used in the pivotal trials and distinguishes
patients with MCI (CDR 0.5) from normal elderly with
sensitivity of 74% and specificity of 86%. The NPIQuestionnaire is a brief version of the NPI that can be
completed by the informant and reviewed by the clinician
(58). These three tools are related to or derived from
instruments used in the aducanumab pivotal trials. The
Functional Activities Questionnaire (FAQ) is a functional
rating scale relevant to early AD and is sufficiently brief
to be used to assess functional abilities in patients treated
with aducanumab (59). The FAQ has good discriminant
validity in distinguishing MCI from dementia and
performed similarly to the ADCS-ADL-MCI scale in
comparative studies (60). These tools are sufficiently brief
to be used in practice settings and could be considered
for use in evaluating patients receiving aducanumab.
Clinicians familiar with CDR administration may
consider annual administration of this instrument to
assess patient cognitive and functional abilities. The
Expert Panel recommends that objective, validated tests
to be used longitudinally to assess patients treated with
aducanumab.

Stopping therapy
The appropriate timing and strategies for stopping
aducanumab therapy have not been studied. Stopping
treatment might be informed by patient preferences, care
partner decisions, or clinician recommendations based
on a perceived lack of effect, ARIA-related concerns,
or inability of the patient to adhere to the treatment
regimen. Aducanumab should be stopped in all
patients manifesting severe symptoms (e.g., seizures,
stroke-like manifestations) in the presence of ARIA.
Stopping treatment in other ARIA-related circumstances
depends on whether ARIA-E resolves after suspending
therapy, whether ARIA-H stabilizes when treatment
is withheld, the patient’s clinical status, and clinician-
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patient alignment on the benefit/harm ratio of resuming
treatment.
Aducanumab has not been tested in patients with
moderate or severe AD and progression into the more
advanced phases of AD will prompt reassessment of
treatment continuation. Progression into moderate
dementia is signaled by progression to CDR global score
of 2.0, decline of MMSE scores below 20, and loss of
autonomy on key ADLs. The Expert Panel recommends
that clinicians carefully review the evidence of benefit and
the potential risk in patients who progress to moderate
dementia after appropriate use of aducanumab in early
AD.

Primary Care Clinicians collaboration
The availability of aducanumab may create a demand
for detection, diagnosis and treatment of early AD that
can overwhelm an unprepared healthcare system (61).
Providing treatment with aducanumab requires high
proficiency and sufficient resources including close
collaborations with comprehensive multi-disciplinary
teams. With too few specialists currently available to
respond to the possible number of patients who
are candidates for treatment, there are opportunities
to forge new models of hub-and-spoke dementia
specialist-primary care collaborations and peer-to-peer
counseling to partially fill these needs and respond to
workforce gaps. The Expert Panel recommends including
community organizations, Alzheimer Association
chapters, primary care clinicians, memory-care enabled
nurses and nurse practitioners, and other creative
collaborations and solutions to meet the needs of patients
seeking care and encountering the difficulty of being
assessed because of shortages of memory care specialists
in the current health care system (62-64).

Appropriate Patient Discussions
Aducanumab is an unprecedented therapy; it
is the first drug approved for treatment of AD based
on plaque lowering and addressing the underlying
pathophysiology of AD. Clinicians, patients, care
partners, and stakeholders of the healthcare system must
learn and adjust to the new therapeutic circumstances.
Discussions with patients and care partners are
particularly important. They require information
regarding the possible benefits of aducanumab, the side
effects including ARIA, and the likely need for long
term adherence to treatment. Dementia medication
discontinuation rates have been shown to be higher in
African American and Hispanic patients than White
patients; racially and ethnically appropriate strategies
may be required to optimize adherence (65). Referral to
the Alzheimer ’s Association (www.alz.org) and other
trusted community sources can assist the clinician in
providing reliable information.

Aducanumab Treatment in Non-AD AmyloidBearing Conditions and Atypical AD
Autosomal dominant AD is produced by mutations
of presenilin 1, presenilin 2, or the amyloid precursor
protein gene. Patients typically develop amyloid
plaques as evidenced by amyloid PET in their mid to
late 30’s and progress to MCI due to AD and mild AD
dementia at age 45 to 55 (66). The individuals have the
canonical features of AD at autopsy (67). Few if any of
these patients were included in the aducanumab clinical
trials. The Expert Panel Recommends that if patients
with autosomal dominant AD meet all other criteria for
aducanumab treatment described in Table 1, they could
be considered candidates for aducanumab and the option
can be discussed with families. They should be informed
of the scarcity of data in patients with the inherited form
of AD.
Individuals with Down syndrome essentially
uniformly develop brain amyloid plaques and often have
symptoms of dementia in midlife (68, 69). The presence
of amyloid plaques in Down syndrome suggests that
treatment with aducanumab may be beneficial. There are
many differences between Down syndrome and late onset
AD, and the Expert Panel recommends against treating
Down syndrome patients with aducanumab until more
data are available.
Patients with AD may present with atypical syndromes
such as logopenic aphasia, posterior cortical atrophy, or
frontal AD (70). These patients have metabolic scans that
reflect the regional dysfunction corresponding to their
clinical presentation; other biomarkers are characteristic
of AD (71). Few patients with atypical features were
included in the aducanumab trials. The Expert Panel
recommends that if patients with atypical AD meet
all the criteria for the appropriate use of aducanumab,
they can be considered as candidates for aducanumab
treatment while cautioning patients and families that little
information regarding use of aducanumab is available on
patients with these clinical profiles.
Patients with dementia with Lewy bodies (DLB)
have MCI that progresses to dementia. They have
characteristic clinical features including parkinsonism,
visual hallucinations, fluctuating cognition, and rapid eye
movement sleep behavior disorder (72). Patients with
DLB may have pure Lewy body pathology or may have
concomitant Lewy body changes and Aβ plaques. Those
with Aβ plaques will have positive amyloid PET imaging
(73). The Expert Panel Recommends that patients with
DLB not be treated with aducanumab; the effect of
treatment in patients with mixed amyloid and Lewy body
pathology is unknown.
The ability to image cognitively normal individuals or
conduct lumbar puncture and CSF analyses allows the
detection of persons in the preclinical phases of the AD
continuum. These individuals have amyloid plaques in
the brain but are cognitively normal. All participants in
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Table 5. Resources needed for the appropriate use of aducanumab (Expert Panel Recommendations)

• Clinicians skilled in the detection and recognition of early AD

• Amyloid PET access or access to individuals with lumbar puncture expertise

• Experts in amyloid PET interpretation or CLIA-certified laboratory available for CSF measurements

• Infusion resources (office/clinic; general infusion center; AD-specific infusion center; home infusion with visiting nurse)
• MRI access

• Experts proficient in recognition of ARIA on MRI

• Experts proficient in clinical recognition and management of ARIA
• Family and patient education and support resources

• Clinicians and staff who deliver culturally competent care

• Genetic counseling available for patients with questions regarding implications of APOE genotyping and interpretation of genetic testing

the aducanumab clinical trials were symptomatic and
met criteria for MCI due to AD or mild AD dementia.
There are no data on the utility of treating individuals
in the preclinical disease state with aducanumab. The
Expert Panel recommends against treating patients in
the preclinical phase of AD with aducanumab until
additional data are available.
Care partners seek means of improving quality of
life for their loved one regardless of the degree of the
patient’s dementia-related disability. Patients with
moderate to severe AD and their caregivers will seek
information about aducanumab and may wish to
be treated. There are no data available on the use of
aducanumab in moderate and severe AD. The Expert
Panel recommends against beginning aducanumab
therapy in patients with moderate to severe AD (e.g,
those with cognitive deficits beyond mild severity
and requiring substantial assistance with activities of
daily living). These patients require comprehensive
compassionate care, and their support must continue
regardless of DMT therapy status. Multidisciplinary
interventions at this stage can significantly improve
quality of life (64, 74).
The amyloid, tau, neurodegeneration (AT(N))
framework is influential in the biomarker classification
of AD (75). Using this approach, A+T-N-, A+T+N-, and
A+T+N+ patients would be considered candidates for
treatment with aducanumab if they have early AD and
meet all treatment criteria (Table 1). A+T-N+ patients
may have some disorder such as vascular pathology in
addition to amyloidosis that may impact aducanumab
therapy. Further evaluation of these patients is required
before proceeding with therapy.
Patients with cerebral amyloid angiopathy may have
positive amyloid PET (76). Use of aducanumab in these
patients may promote ARIA (77). The Expert Panel
recommends that aducanumab not be used in patients
with cerebral amyloid angiopathy.

Potential Future Changes in Appropriate Use of
Aducanumab
AD science is evolving rapidly in both diagnostic and
therapeutic technologies. Blood tests that assist in the

diagnosis of AD could have a transformative influence
on the care of AD patients and the appropriate use of
aducanumab. Blood assays that determine the Aß42/40
ratio have good correspondence with amyloid PET status
(receiver operator curse area under the curve [AUC]
0.88) and this improves when combined with patient
age and APOE-4 genotype (AUC 0.94) (78). Plasma
hyperphosphorylated tau (p-tau) 181 and p-tau 217 are
abnormal in early AD and correlates significantly with
amyloid burden on PET (79-81). One of these plasmabased markers or a panel of markers possibly including
APOE genotype could eventually provide a diagnosis
of brain amyloidosis in patients with symptoms of early
AD or could function as a case-finding tool to identify
patients likely to have an abnormal amyloid PET.
Blood tests may not be the only means of identifying
amyloidosis in patients with the clinical syndrome of
early AD. Amyloid is deposited in the retina in AD, and
retinal imaging might be another means of detecting
central nervous system amyloidosis (82, 83). Digital
biomarkers could play a role in case finding or diagnostic
confirmation. Voice and language analyses, for example,
are promising means of identifying early AD (84, 85).
Currently, aducanumab treatment is administered with
the plan of continuing at least until the patient reaches
the moderate stage of AD dementia. However, once
significant amyloid lowering has been achieved it may
be possible to reduce the frequency of infusions. The
durability of amyloid lowering was explored in a trial
with another amyloid-targeting monoclonal antibody (86)
with encouraging results.
Prevention of AD is an important goal of AD research.
Trials of aducanumab during the preclinical phases
of AD when the brain has high levels of amyloid but
cognition remains largely normal may expand the range
of individuals appropriate for treatment (87)
Patients with Down syndrome that meet all the other
criteria for treatment with aducanumab may become
treatment-eligible when additional studies have been
conducted and additional data are available (88).

Summary
Aducanumab is a new treatment for AD. It provides
opportunities and challenges for its introduction into
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the management of AD patients. Aducanumab requires
substantial infrastructure for appropriate administration:
expert clinicians skilled in recognition of early AD;
amyloid PET or lumbar puncture capability; experts in
amyloid PET interpretation or CSF analysis: infusion
center availability; and access to MRI and experts in
recognition and management of ARIA (Table 5). Genetic
counseling may be required in some circumstances, and
all patients and care partners require education and
support. Building this infrastructure for the appropriate
use of aducanumab will require time, resources, and
creative planning. Appropriate use of aducanumab
requires a commitment to patient-centered care and bestpractices for the safe delivery of this new treatment.
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